Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Pituitary Neoplasms 7Prolactinoma 5Polycystic Ovary Syndrome 3Pituitary ACTH Hypersecretion 3Hyperprolactinemia 2Acromegaly 2Recurrence 1Prostatic Neoplasms 1Prolactin Deficiency, Isolated 1Ovarian Hyperstimulation Syndrome 1Neuroendocrine Tumors 1Neoplasms 1Melanoma 1Dumping Syndrome 1Breast Neoplasms 1Brain Neoplasms 1Adrenocortical Hyperfunction 1Adenoma 1ACTH-Secreting Pituitary Adenoma 1

Interventions

Temozolomide 162Radiosurgery 114Radiotherapy 99Bevacizumab 95Magnetic Resonance Spectroscopy 64Carboplatin 48Etoposide 34Surgical Procedures, Operative 33Irinotecan 33pembrolizumab 32Nivolumab 32Cyclophosphamide 32Erlotinib Hydrochloride 31Radiation 29Carmustine 28Cisplatin 25Lomustine 24Trastuzumab 23Ipilimumab 23Filgrastim 23Vincristine 20Mental Status and Dementia Tests 20Aminolevulinic Acid 19Topotecan 18Pemetrexed 18Capecitabine 18Specimen Handling 17Sorafenib 15Radiotherapy, Intensity-Modulated 15Imatinib Mesylate 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Brain Neoplasms × Cabergoline × Clear all
NCT00376064 2017-03-06

Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly

Novartis

Phase 4 Completed
20 enrolled
CNSEndocrine

Acromegaly, Brain Neoplasms, Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡